Abstract:OBJECTIVES: Cell-free DNA based non-invasive prenatal testing (NIPT) has been shown with closeto-diagnosis sensitivity and specificity in detecting fetal T21, T18, and T13. Future development of this technology focuses on detection of other chromosomal aneuploidies, and more importantly chromosome copy number variants (CNVs) and single-gene mutations. Validation studies were carried out to demonstrate the feasibility of detecting CNVs and single-gene disease by exploiting the cell-free DNA testing strategy and existing NIPT platforms. METHOD: For testing CNVs, 35 plasma samples with known fetal CNVs (>10 Mb in size) were recruited, together with 1077 plasma samples with normal fetal karyotypes as the control. The samples were blindly tested using the routine NIPT testing pipelines adopted at the clinical laboratories of BGI, and analyzed with the proprietary FCAPS protocol. Results were compared to the karyotyping results to calculate the sensitivity and specificity of the NIPT test. For testing single-gene disease, we developed a unique haplotype-assisted approach which was validated in a Maple Syrup Urine Disease (MSUD) case. In a trio family (father, mother in early pregnancy, and proband), targeted sequencing (180X) of the known genes causing MSUD was used to identify the disease causative mutations in the proband child and parents. At 13 gestational weeks, maternal plasma DNA and genomic DNA of the trio family were tested with a customized array at the sequencing depth of 40X and 20X respectively to retrieve the SNPs information for the purpose of parental haplotypes deduction. Linkage analysis and Hidden Markov Model were then used to construct the fetal genotype and haplotype flanking the MSUD mutation region. RESULTS: For CNV detection, with on average 4–5 M reads per sample and the existing NIPT platforms, we were able to use the FCAPS analytic protocol to identify 32 positive samples in total of 35, and generated 6 false positive cases, leading to overall sensitivity and specificity of 91.4% and 99.4% respectively. False positive rate and false negative rate of the test were 0.56% and 0.28% respectively. We also showed that with an increased sequencing depth, the detection power of the test can be further improved. In the MUSD case, deep targeted sequencing in the trio family identified that the proband child carries a missense mutation and a large deletion on BCKDHA gene, which were inherited from the mother and father respectively. With the SNP markers of the proband and parents, parental haplotype of chromosome 19 in 6148 loci were recovered. After fetal haplotype construction, the same alleles as that of the proband in the causative gene BCKDHA were inherited to the fetus, indicating that the fetus is a MSUD patient. This result was later confirmed by invasive diagnosis, and led to a well-informed decision after post-test counselling. CONCLUSIONS: We demonstrate the successful application of NIPT in detection of CNVs larger than 10 Mb without changing much to the current pipelines of aneuploidy detection. It has the potential to be integrated into the current NIPT test and offer extra benefits to the clinical service. The haplotype-assisted approach we developed requires minimum genetic information to accurately predict fetal condition. It has the clinical potential for noninvasive prenatal diagnosis of single gene disease for family with a proband child and seeks a second healthy child.

Novel Real-Time Pcr Assay for Rapid Prenatal Diagnosis of Down Syndrome: A Prospective Study of 563 Amniocytes

Quantitative Real‐time PCR Technique for Rapid Prenatal Diagnosis of Down Syndrome

[Application of Real-Time Fluorescence Quantitative Polymerase Chain Reaction Techniques for Prenatal Diagnosis of Down Syndrome].

Noninvasive Prenatal Screening of Fetal Aneuploidy without Massively Parallel Sequencing

[Rapid Diagnosis of Down's Syndrome by Multiplex Real-Time Fluorescence Relative Quantitative PCR].

Prenatal Diagnosis of Down Syndrome Using Cell-Free Fetal DNA in Amniotic Fluid by Quantitative Fluorescent Polymersase Chain Reaction.

Clinical application of noninvasive prenatal testing for the detection of trisomies 21, 18, and 13: a hospital experience.

Noninvasive detection of chromosomal CNV and single gene disease by massively parallel sequencing of cfDNA

Study on rapid genetic diagnosis of trisomy 21

Detection of Aneuploidy with Digital PCR

Molecular Cytogenetic Detection of Trisomy 21 in Interphase Nuclei and Metaphase Chromosomes.

Detection of Cell-Free Fetal DNA in Maternal Serum for a New Prenatal Screening Marker of Down's Syndrome

Chip-Based Digital PCR Approach Provides A Sensitive and Cost-Effective Single-Day Screening Tool for Common Fetal Aneuploidies-A Proof of Concept Study

A Quality Assurance Scheme for Prenatal Detection of Aneuploidy Based on Developing Chimeric Quality-Control Cells

The Application of NIPT Using Combinatorial Probe-Anchor Synthesis to Identify Sex Chromosomal Aneuploidies (scas) in a Cohort of 570 Pregnancies

Rapid Detection of Chromosomal Aneuploidies by Multiplex Ligation-Dependent Probe Amplification

[Application of Multiplex Quantitative Fluorescent PCR with Non-Polymorphic Loci in Prenatal Diagnosis].

Combined diagnosis of QF‐PCR and CNV‐Seq in fetal chromosomal abnormalities: A new perspective on prenatal diagnosis

Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening

A Multiplex Droplet Digital PCR Assay for Non-Invasive Prenatal Testing of Fetal Aneuploidies.

External Quality Assessment of Prenatal Diagnosis of a Rare and Subtle Chromosomal Structural Abnormality.